Maxacalcitol

A novel dual-modal approach combining optical coherence tomography (OCT) and Raman spectroscopy has demonstrated 96.9% accuracy in differentiating melanoma from benign lesions when paired with machine learning algorithms.

Clinical investigation experts at OCT Medical Devices 2025 conference highlight that regulatory compliance challenges primarily originate at the trial site level, emphasizing the critical role of data quality.

Oculis Holding AG's OCS-05 met the primary safety endpoint and achieved statistically significant results in key secondary efficacy endpoints in the ACUITY trial.

Sage Therapeutics' dalzanemdor failed in the Phase II DIMENSION trial for Huntington's disease, leading to the discontinuation of its development.

The 12th Annual Outsourcing in Clinical Trials & Clinical Trial Supply Nordics meeting in Copenhagen will bring together experts to explore current trends in trial operations, outsourcing, and supply chain management.